Repros Therapeutics Announces Cancellation of FDA Advisory

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Repros Therapeutics Announces Cancellation of FDA Advisory Committee Meeting to Review Enclomiphene for the Treatment of Secondary Hypogonadism

THE WOODLANDS, Texas, Oct. 29, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq: RPRX ) today announced that the Division of Bone, Reproductive and Urologic Products of the U.S. Food and Drug Administration (FDA) has cancelled the scheduled November 3, 2015 advisory committee to review the Company's New Drug Application (NDA) for its enclomiphene product candidate, formerly known as Androxal®, due to questions that arose late in the review regarding the bioanalytical method validation that could affect interpretability of certain pivotal study data.

The FDA has expressed its willingness to work with Repros to address these questions. The FDA accepted the NDA for review on April 1, 2015 and later assigned a Prescription Drug User Fee Act (PDUFA) goal date of November 30, 2015.

Conference Call Details:

Time: Thursday, October 29, 2015 – 3:30 PM Eastern  Participant Dial-In Number (Domestic): 888-225-7740; International: 303-223-2694

Any investor inquiries directed to the Company should be placed through our investor relations contact noted below.

About Repros Therapeutics Inc.®

Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.

Forward-Looking Statements

Any statements made by the Company that are not historical facts contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to various risks, uncertainties and other factors that could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. These statements often include words such as "may," "will," "expect," "anticipate," "continue," "estimate," "project," "intend," "believe," "plan," "seek," "could," "can," "should" or similar expressions. These statements are based on assumptions that the Company has made in light of the Company's experience in the industry, as well as the Company's perceptions of historical trends, current conditions, expected future developments and other factors the Company believes are appropriate in these circumstances. Forward-looking statements include, but are not limited to, those relating to possible approval of the NDA by the FDA and the timeline for such approval and potential benefits and uses of the label for the product candidate and its commercial potential. Such statements are based on current expectations that involve a number of known and unknown risks, uncertainties and other factors that may cause actual events to be materially different from those expressed or implied by such forward-looking statements, including risks that the advisory committee meeting will not occur on the scheduled date, that the FDA will not complete their review of the NDA by the PDUFA date, that the FDA may not ultimately approve the product candidate, the risk that any marketing approvals, if granted, may have significant limitations on use, that even if the NDA is approved, the Company may not be able to successfully commercialize the product candidate, risks relating to the Company's ability to protect its intellectual property rights and such other risks as are identified in the Company's most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Repros Therapeutics or at www.sec.gov . Repros disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please visit the Company's website at http://www.reprosrx.com .

Investor Relations: Thomas Hoffmann The Trout Group (646) 378-2931

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NetEase Margins Hold Firm as Game Revenue Slips Again

Updated Category News Views 123

A game publisher can look tired at the top line and still be doing plenty right underneath the hood. NetEase’s third-quarter 2026 report is that kind of animal: revenue eased, yet costs behaved, profit rebounded from the prior quarter, and the balance sheet remains absurdly well stocked. For investors in NASDAQ:NTES, this was not a clean victory lap. It was a reminder...

Continue Reading
Gene Editing’s Steady Revenue Engine Is Taking Shape

Updated Category News Views 112

Gene editing is finally starting to look less like a science-fair moonshot and more like a working supply chain. That distinction matters. The latest market estimate puts the global gene editing market at $5.23 billion in 2026 and projects $8.49 billion by 2031, a 10.1% compound annual growth rate. Respectable growth, certainly, but the real investment story is not a...

Continue Reading
Shanghai Import Expo Draws 4,000 Global Companies Again

Updated Category News Views 175

Shanghai spent last week making a rather pointed commercial argument: China wants to be seen buying, not merely selling. The ninth China International Import Expo, or CIIE, brought together more than 4,000 overseas companies and participants from 162 countries, regions and international organizations. That is a serious gathering by any reasonable measure, even if the...

Continue Reading
Würk's Bryte AI Targets Payroll's Costly Friction Points

Updated Category News Views 104

Payroll mistakes are the sort of paper cuts that suddenly turn into a hospital bill for an employer. Würk’s Nov. 19 launch of Bryte AI goes straight at that ugly reality in cannabis, beverage alcohol, and other heavily regulated workplaces, where a bad time entry, missed document, or misunderstood policy can create a far more expensive mess than ordinary office...

Continue Reading
Greenberg Traurig Builds Real Estate Bench Further

Updated Category News Views 47

Two real estate lawyers rarely move a market, but they can tell you where the legal work is getting sticky. Greenberg Traurig’s November 19 addition of Steven A. Fein and Kelsey Thayer is not some grand macroeconomic pronouncement, and nobody should pretend otherwise. It is, however, a pretty sensible read on the messy corners of commercial property finance: joint...

Continue Reading
CustomerInsights.AI Fast 500 Nod Tests Its AI Model

Updated Category News Views 44

Pharma’s analytics mess is exactly where CustomerInsights.AI has chosen to make its stand. The Scottsdale company’s inclusion in Deloitte’s 2026 Technology Fast 500, announced November 19, is a useful signal that its pitch is finding buyers: life-sciences businesses want AI to do actual commercial work, not sit in a lab demo collecting dust. Still, a Fast 500 badge...

Continue Reading
Securitize Tests the IPO Clock With Anthropic Tokens

Updated Category News Views 93

Anthropic did not even get a full trading day to itself before the tokenization crowd arrived. Securitize says Anthropic stock became available through Securitize Stocks on Solana on the company’s first day as a public company, a loud little signal that the old IPO playbook is being prodded from the edges. For investors, this is not merely another crypto-flavored...

Continue Reading
SDG&E's 21-Year Reliability Run Has Real Investor Weight

Updated Category News Views 37

Seventy minutes without power in a year is the sort of number most people ignore until their refrigerator quits humming. For San Diego Gas & Electric customers, though, it is a meaningful operating result: roughly 70 minutes annually from unplanned outages, on average, over the past decade, alongside fewer than one sustained outage per customer each year. SDG&E has also...

Continue Reading
Bella Rio's Proposed Preferred B Share Giveaway Plan

Updated Category News Views 46

A founder handing over two million of his own common shares is the sort of detail that makes investors stop stirring their coffee. Bella Rio Consulting, the company behind ROCK'N Vodka and Bella Rio Bourbon, says co-founder and Vice President Andy Roiniotis proposes to contribute 2,000,000 personally held Common shares for reclassification into Preferred Series B shares....

Continue Reading
Stanford Forum Puts Industrial AI in the Real World

Updated Category News Views 166

Factory Data Is Not a Free Lunch A factory dataset is worth precisely nothing if its owner cannot control it. That was the hard-nosed thread running through the ASI City Forum at Stanford on November 17: industrial AI is not just about smarter models or splashy chip announcements. It is about whether manufacturers will trust a system with proprietary operating data,...

Continue Reading

Top 5 Most Recently Viewed Articles

Alvopetro Energy Ltd. Reports Record Sales Volumes

Updated Category News Views 127

Alvopetro Energy Ltd. Reports Strong Sales Volumes Alvopetro Energy Ltd. has reported commendable sales volumes for June 2025, reaffirming its position in the energy sector. The company, identified by its ticker symbols ALV (on the TSX Venture Exchange) and ALVOF (on the OTCQX), indicated a notable production rate of 2,514 barrels of oil equivalent per day (boepd) based...

Continue Reading
Mannatech Achieves New Stock Milestone with 52-Week High

Updated Category News Views 177

Mannatech Reaches Remarkable Peak in Stock Performance Mannatech, Incorporated (MTEX), a company dedicated to offering global wellness solutions, has recently achieved a noteworthy milestone by reaching a 52-week high with its stock price hitting $13.34. This impressive rise indicates a substantial increase in investor confidence, as the shares have surged by an...

Continue Reading
Exciting Developments Ahead for FAIRWOOD's Second Season

Updated Category News Views 240

FAIRWOOD Returns with a New Season The popular comedy series FAIRWOOD has officially been renewed for a second season, much to the delight of its fans. The show's creators, renowned musical duo Rusty and Clark Fairwood, along with the talented showrunner Bud Schaetzle, are back at the helm to deliver more engaging episodes. With all six episodes of the first season now...

Continue Reading
Celebrating Pioneers in the $6.8 Trillion Wellness Movement

Updated Category News Views 330

Leaders Transforming the Global Wellness Economy The Global Wellness Summit (GWS), renowned for gathering visionaries in the $6.8 trillion wellness economy, recently wrapped up its 19th annual conference held at an upscale venue. This prestigious gathering celebrated outstanding contributions through the Global Wellness Awards, recognizing individuals who have made...

Continue Reading
CRED iQ & TractIQ Push $50B of Data into AI Era

Updated Category News Views 5

AI-Driven Innovation in Self-Storage Market Mark my words, folks, the marriage of data and AI is reshaping industries faster than a stock split on Wall Street. CRED iQ and TractIQ are venturing into this fast-paced union. Just north of Philadelphia, CRED iQ has sealed a deal with TractIQ, a frontrunner in self-storage data solutions, to funnel a cool $50 billion worth of...

Continue Reading